Tabriz Medical University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Tabriz Iran (Islamic Republic of) (1947)

Organization Overview

First Clinical Trial
2007
NCT00636428
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Alireza Javadzadeh | Cardiovascular research center, Tabriz University of Medical Sciences, Tabriz, Iran | Deputy for translational medicine of SCARM institute | Farid Masoud | Head of SCARM Cell therapy Center | Head of SCARM institute | Head of SCARM Institute | liver &Gastrointestinal Research center of tabriz medical university | Pharmaceutics Department, Pharmacy Faculty | Pharmacy Faculty | SCARM institiute | SCARM institute | SCARM Institute, Tabriz, Iran | Stem Cell and Regenerative Medicine Institute | tabriz medical university | Tabriz Research Center for Gastroenterology and Liver Diseases | Tabriz university of medical science | Tabriz University of Medical Sciences

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abortion, Habitual (Phase 2)

Abortion, Spontaneous (Phase 2)

Alopecia (Phase 3)

Alopecia Areata (Phase 3)

Burns (Phase 2)

Central Serous Chorioretinopathy (Phase 2)

Fetal Death (Phase 2)

Heart Failure (Phase 2)

Hemophilia A (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Multiple Sclerosis (Phase 2)

Optic Nerve Diseases (Phase 3)

Optic Nerve Injuries (Phase 3)

Osteoarthritis (Phase 2)

Peripheral Nervous System Diseases (Phase 3)

Sclerosis (Phase 2)

Spondylitis (Phase 2)

Spondylitis, Ankylosing (Phase 2)

Thalassemia (Phase 4)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 22
  • # of Trial APIs: 25